According to a media release issued late yesterday by Johnson & Johnson, the combination of apalutamide (Erleada) + androgen deprivation therapy (ADT) has met the primary study endpoints in the so-called TITAN trial. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, castration-sensitive, Erleada, hormone-sensitive, mCSPC, metastatic, mHSPC, outcome, TITAN, trial | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 